NASDAQ:TNFA TNF Pharmaceuticals (TNFA) Stock Price, News & Analysis $0.20 +0.01 (+4.74%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$0.20 0.00 (-0.55%) As of 06:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About TNF Pharmaceuticals Stock (NASDAQ:TNFA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TNF Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.19▼$0.2150-Day Range$0.17▼$0.4652-Week Range$0.16▼$2.16Volume1.96 million shsAverage Volume534,040 shsMarket Capitalization$2.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Read More… Receive TNFA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TNF Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TNFA Stock News HeadlinesComparing OncoCyte (NASDAQ:OCX) and TNF Pharmaceuticals (NASDAQ:TNFA)May 1 at 2:51 AM | americanbankingnews.comTNF Pharmaceuticals (TNFA) & Its Competitors Head to Head ComparisonApril 30 at 2:09 AM | americanbankingnews.comJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportunities could be even bigger.May 2, 2025 | Paradigm Press (Ad)TNF Pharmaceuticals (TNFA) and The Competition Financial ContrastApril 30 at 2:09 AM | americanbankingnews.comFinancial Contrast: Oruka Therapeutics (NASDAQ:ORKA) versus TNF Pharmaceuticals (NASDAQ:TNFA)April 28, 2025 | americanbankingnews.comHead to Head Comparison: TNF Pharmaceuticals (TNFA) vs. Its CompetitorsApril 27, 2025 | americanbankingnews.comFinancial Comparison: TNF Pharmaceuticals (TNFA) & Its PeersApril 26, 2025 | americanbankingnews.comTNF Pharmaceuticals uses AI to refine patient selection for trialsApril 24, 2025 | uk.investing.comSee More Headlines TNFA Stock Analysis - Frequently Asked Questions How have TNFA shares performed this year? TNF Pharmaceuticals' stock was trading at $1.15 on January 1st, 2025. Since then, TNFA shares have decreased by 82.5% and is now trading at $0.2011. View the best growth stocks for 2025 here. How were TNF Pharmaceuticals' earnings last quarter? TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) posted its quarterly earnings results on Friday, April, 11th. The company reported ($0.66) EPS for the quarter. How do I buy shares of TNF Pharmaceuticals? Shares of TNFA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TNF Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that TNF Pharmaceuticals investors own include Amprius Technologies (AMPX), Archrock (AROC), Axon Enterprise (AXON), PACCAR (PCAR), Bitfarms (BITF), Bitfarms (BFARF) and BigBear.ai (BBAI). Company Calendar Last Earnings4/11/2025Today5/02/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNFA CIK1321834 Webtnfpharma.com Phone(856) 848-8698Fax856-848-0269Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($11.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-180.71% Return on Assets-84.27% Debt Debt-to-Equity RatioN/A Current Ratio1.72 Quick Ratio1.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.21 per share Price / Book0.03Miscellaneous Outstanding Shares10,133,000Free Float2,722,000Market Cap$2.04 million OptionableN/A Beta2.43 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:TNFA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TNF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TNF Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.